Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy

Blood (2021) 138 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2021-145530

Published: 2021

Journal Articles

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

Lyndsey Flanagan, Michael E. O'Dwyer, Philip Murphy, John Quinn, Siobhan Glavey, Triona Ni Chonghaile

Blood (2021) 138 (Supplement 1): 4703.

https://doi.org/10.1182/blood-2021-147185

Published: 2021

Journal Articles

Primary Myeloma Cell Induced Von Willebrand Factor Release from the Endothelium Is Mediated By VEGF and Attenuated By Heparin

Claire Comerford, Sukhraj Pal Singh Dhami, Philip Murphy, Sean Patmore, Siobhan Glavey, John Quinn, Jamie M. O'Sullivan

Blood (2021) 138 (Supplement 1): 3141.

https://doi.org/10.1182/blood-2021-149134

Published: 2021

Journal Articles

Red Blood Cells from COVID-19 Patients Show Evidence of Increased Oxidative Stress and Increased Lactate Influx

Philip Murphy, Edel Mullen, Stephen Bergin, Geraldine Healy, Michelle Lavin, John Quinn, Siobhan Glavey

Blood (2021) 138 (Supplement 1): 928.

https://doi.org/10.1182/blood-2021-146305

Published: 2021

Journal Articles

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Mohamed Bakri Mohamed, Seán R Millar, Vitaliy Mykytiv, Rose McMorrow, Conan Donnelly, Paul M Walsh, Eamonn O'Leary, Nina Orfali, Philip Murphy, Paul V. Browne, John Quinn, Peter O'Gorman, Ruth Clifford, Ezzat El Hassadi, Oonagh Gilligan, Janusz Krawczyk, Michael E. O'Dwyer, Eva Szegezdi, Mary R Cahill

Blood (2021) 138 (Supplement 1): 1218.

https://doi.org/10.1182/blood-2021-149832

Published: 2021

Journal Articles

Non Double-Hit Diffuse Large B Cell Lymphoma Treated with R-CHOP Has Excellent Overall Survival If Interim Scan Shows Partial or Complete Response

Philip Murphy, MD, Siobhan Glavey, MDPhD, Oscar Breathnach, MD, Philip W Murphy, Liam Grogan, MD, Patrick Morris, MD, John Quinn, MB,PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-138402

Published: 2020

Journal Articles

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

Sukhraj Pal Singh Dhami, MSc, BSc, Andrea Tirincsi, MSc, BSc, Denis V Baev, PhD, Janusz Krawczyk, MD, John Quinn, MD PhD, Eva Szegezdi, PhD

Blood (2018) 132 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2018-99-118619

Published: 2018

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Saad Ahmed, MBBS, Mattia Cremona, PhD, Sinead Toomey, PhD, Mark Catherwood, PhD, Stephen Bergin, BS, Paul Kennedy, BS, Bryan Hennessy, MD, Patrick Thornton, MB, FRCPath, John Quinn, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 5532.

https://doi.org/10.1182/blood-2018-99-114104

Published: 2018

Journal Articles

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Aisling Barrett, John Quinn, MD PhD, Siobhan Glavey, MD PhD, Jeremy Sargent, FRCPath, Michelle Lavin, MB, PhD FRCPath, Patrick Thornton, MB, FRCPath, James S O'Donnell, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 1223.

https://doi.org/10.1182/blood-2018-99-116148

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 3163.

https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163

Published: 2017

Journal Articles

Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations

Saad Ahmed, MBBS, MRCP, John Quinn, Mark Catherwood, Patrick Thornton, Stephen Bergin, Paul Kennedy, Sally Elsir, Bryan Hennessy, Philip Murphy

Blood (2017) 130 (Supplement 1): 5323.

https://doi.org/10.1182/blood.V130.Suppl_1.5323.5323

Published: 2017

Journal Articles

From a DOAC to Warfarin: Reasons Why Patients Switch

Aisling Barrett, MB, BCh, BAO, MRCPI, Sahar Khan, MRCPI, Margaret Moore, RGN, Patricia Ferrins, RGN, BSc, Jeremy Sargent, FRCPath, Patrick Thornton, Philip Murphy, John Quinn

Blood (2017) 130 (Supplement 1): 4910.

https://doi.org/10.1182/blood.V130.Suppl_1.4910.4910

Published: 2017

Journal Articles

Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS)

Akhil Khera, Katja Kimberger, Fotios Panitsas, Chris Winearls, John Quinn, Simon Stern, Neil Rabin, Bassam Alchi, Ian Roberts, Richard Haynes, Karthik Ramasamy

Blood (2016) 128 (22): 5948.

https://doi.org/10.1182/blood.V128.22.5948.5948

Published: 2016

Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Blood (2016) 128 (22): 2117.

https://doi.org/10.1182/blood.V128.22.2117.2117

Published: 2016

Journal Articles

Strong Correlation Between CTLA-4 and LEF1 Gene Expression Levels in CLL: Targeting of the Wnt/β-Catenin Pathway May Adversely Affect CTLA-4 Expression and Function

Philip T Murphy, MD, Gary Lynch, Stephen Bergin, John Quinn, MD PhD, Siobhan Glavey, MD, Philip W Murphy, Paul Kennedy

Blood (2016) 128 (22): 5571.

https://doi.org/10.1182/blood.V128.22.5571.5571

Published: 2016

Journal Articles

The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12

Sally Elsir Mohammed, MBBS, MRCP(UK), Philip Murphy, MD, John Quinn, Patrick Thornton, FRCPath, Stephen Bergin, Bryan Hennessy

Blood (2015) 126 (23): 5271.

https://doi.org/10.1182/blood.V126.23.5271.5271

Published: 2015

Journal Articles

Global Methylation Analysis of Cyclin D1vs D2 Dysregulated Primary Myeloma Samples

Jonathan I Sive, MBChB, Andrew Feber, PhD, Dean Smith, MBBS, John Quinn, MB, PhD, Stephan Beck, PhD, Kwee L Yong, MBChB, PhD

Blood (2014) 124 (21): 3389.

https://doi.org/10.1182/blood.V124.21.3389.3389

Published: 2014

Journal Articles

Impact Of Dialysis-Dependent Renal Failure At Time Of Myeloma Diagnosis On Overall Survival - a 15-Year Single Centre Analysis

Philip T Murphy, MD, MRCPath, Cherisse Baldeo, MB, Patrick O'Kelly, Jeremy Sargant, MB, Patrick Thornton, MB, Mary McCloy, MB, MRCP, MRCPath, Peter Conlon, MB, Colm Magee, MB, Mark Denton, MB, John Quinn, MB, PhD

Blood (2013) 122 (21): 3230.

https://doi.org/10.1182/blood.V122.21.3230.3230

Published: 2013

NARROW

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma

Primary Myeloma Cell Induced Von Willebrand Factor Release from the Endothelium Is Mediated By VEGF and Attenuated By Heparin

Red Blood Cells from COVID-19 Patients Show Evidence of Increased Oxidative Stress and Increased Lactate Influx

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Non Double-Hit Diffuse Large B Cell Lymphoma Treated with R-CHOP Has Excellent Overall Survival If Interim Scan Shows Partial or Complete Response

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Unmutated IGHV and Double Negative CD38/CD49d Predict Good Prognosis and Long Treatment Free Survival (TFS) in Chronic Lymphocytic Leukaemia; Regardless of Genetic Mutations

From a DOAC to Warfarin: Reasons Why Patients Switch

Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS)

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Strong Correlation Between CTLA-4 and LEF1 Gene Expression Levels in CLL: Targeting of the Wnt/β-Catenin Pathway May Adversely Affect CTLA-4 Expression and Function

The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12

Global Methylation Analysis of Cyclin D1vs D2 Dysregulated Primary Myeloma Samples

Impact Of Dialysis-Dependent Renal Failure At Time Of Myeloma Diagnosis On Overall Survival - a 15-Year Single Centre Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only